Jan. 5 at 6:48 PM
LifeMD announced it is now offering Novo Nordisk’s Wegovy pill through its virtual primary care platform, making it the first FDA-approved oral GLP-1 therapy for weight management available via telehealth. Eligible patients can access the drug for as little as
$149 per month, expanding LifeMD’s branded obesity treatment portfolio and deepening its collaboration with Novo Nordisk.
Management said the launch reinforces LifeMD’s position as a preferred virtual destination for evidence-based weight management. The announcement also lifted other weight-management stocks, with WW International rising after unveiling similar access, and GoodRx gaining after confirming nationwide cash-price availability at the same monthly cost.
The FDA approved the oral Wegovy in December 2025 as the first GLP-1 pill for weight management and cardiovascular health, with clinical trials showing average weight loss of 16.6% versus 2.7% with placebo over 64 weeks.
$LFMD $NVO $WW $GDRX